Skip to main content

Table 1 Characteristics of studies included in the meta-analysis

From: Prognostic and clinicopathological significance of MLKL expression in cancer patients: a meta-analysis

Author

Year

Region

Type of Cancer

Sample size (high/low)

Follow-up

(month)

Endpoints

Expression associated with poor prognosis

Assay method

Cut-off value

Survival analysis

NOS score

Method

Zhu et al.

2017

China

Breast Cancer

27/47(74)

94

OS

Low

IHC

High: the sum of the staining intensity and extent scores was higher than 3

NA

6

2

Zhai et al.

2016

China

Gastric Caner

50/67(117)

114

OS

Low

IHC

High: IHC score was no less than 2

Univariate

Multivariate

7

2

Ruan et al.

2015

China

Cervical Squamous Cell Carcinoma

25/29(54)

80

OS

Low

IHC

High: the sum of the staining intensity and extent scores was no less than 4

NA

6

2

He et al.

2013

China

Ovarian Cancer

75/78(153)

102

OS,DFS

Low

IHC

High: the sum of the staining intensity and extent scores was no less than 4

Univariate

Multivariate

7

1

Li et al.

2016

China

Colon Cancer

83/52(135)

95.3

OS,RFS

Low

IHC

High: the sum of the staining intensity and extent scores was no less than 4

Univariate

Multivariate

7

1

Colbert et al.

2013

USA

Pancreatic Adenocarcinoma

74/6(80)

114

OS,RFS

Low

IHC

High: the sum of the staining intensity and extent scores was higher than 1

Univariate

Multivariate

7

1

  1. IHC immunohistochemistry, NA not available, NOS Newcastle-Ottawa Scale, Method: 1 denoted as obtaining HRs directly from publications; 2 denoted as HRs calculated from the total number of events, corresponding p value and data from Kaplan-Meier curves